Denali Therapeutics (DNLI) EBIT (2017 - 2024)
Historic EBIT for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$129.8 million.
- Denali Therapeutics' EBIT rose 205.62% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 14775.98%. This contributed to the annual value of -$487.3 million for FY2024, which is 14775.98% down from last year.
- According to the latest figures from Q4 2024, Denali Therapeutics' EBIT is -$129.8 million, which was up 205.62% from -$123.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' EBIT registered a high of $244.1 million during Q4 2020, and its lowest value of -$132.6 million during Q4 2023.
- Its 5-year average for EBIT is -$62.9 million, with a median of -$81.4 million in 2021.
- Per our database at Business Quant, Denali Therapeutics' EBIT skyrocketed by 52258.73% in 2020 and then tumbled by 16838.98% in 2024.
- Over the past 5 years, Denali Therapeutics' EBIT (Quarter) stood at $244.1 million in 2020, then plummeted by 131.6% to -$77.1 million in 2021, then tumbled by 36.6% to -$105.3 million in 2022, then decreased by 25.85% to -$132.6 million in 2023, then grew by 2.06% to -$129.8 million in 2024.
- Its last three reported values are -$129.8 million in Q4 2024, -$123.2 million for Q3 2024, and -$116.6 million during Q2 2024.